A Phase 3, Randomized, Double-Blind, Active-Controlled, Multi-Center Extension Study to Evaluate Safety and Efficacy of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
TerminadoFase 3ClinicalTrials.gov
ID: NCT00998686Tipo: INTERVENTIONALInicio: 1 de nov de 2009Fin estimado: 1 de nov de 2011
The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.
Elegibilidad
Edad mínima: 18 YearsEdad máxima: 85 YearsSexo: ALL
Criterios de inclusión
Completion of all required visits of a qualifying Phase 3 core protocol
Current treatment of Type 2 diabetes mellitus as in PHX1149-PROT302
Criterios de exclusión
Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment
Intervenciones
drug
dutogliptin
400 mg
drug
sitagliptin
100 mg
Ubicaciones
Phenomix Investigational Site 402
Buenos Aires, Argentina
Phenomix Investigational Site 408
Buenos Aires, Argentina
Phenomix Investigational Site 410
Mendoza, Argentina
Patrocinadores
PrincipalPhenomix
ColaboradorForest Laboratories
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A Phase 3, Randomized, Double-Blind, Active-Controlled, M... | EligiMed